

# 2026 FIFA World Cup

## Summary of Biological Threats: June-July 2026

### Clues to a possible bioterrorist attack:

- Single cases of disease due to uncommon, non-indigenous agents in patients with no history suggesting an explanation for illness
- Clusters of patients with similar syndrome with unusual characteristics (e.g., unusual age distribution) or unusually high morbidity and mortality
- Unexplained increase in the incidence of a common syndrome above seasonally expected levels (e.g., increase in influenza-like illness during summer, or with negative tests for influenza and other respiratory viruses).

To report suspected cases, access diagnostic testing, or to obtain more information contact the Division of Disease Control at 215-685-6741 during business hours (8:30am-5:00pm). After hours and on weekends and holidays call 215-686-4514, press 1 for Unified Dispatch, and ask for DDC On-Call staff.

Disease	Clinical Syndrome	Incubation Period	Diagnostic Samples	Diagnostic Assay	Patient Isolation Precautions	Treatment	Post-Exposure Prophylaxis	Comments
<b>Anthrax</b>	<ul style="list-style-type: none"> <li>• Inhalational: febrile prodrome, respiratory distress, bacteremia, meningitis.</li> <li>• CXR: wide mediastinum</li> <li>• Cutaneous: ulcer</li> <li>• GI syndrome: less likely</li> </ul>	1-5 days (up to 42 days described)	Sputum, blood, CSF; stool, ulcer swab or biopsy (BSL-2)	Gram stain, culture, PCR	Standard (no person-to-person transmission).	Cipro 400 mg IV q 8-12 or doxycycline 100 mg IV q 12; plus 1 or 2 additional abx (e.g., rifampin, vancomycin, penicillin, chloramphenicol, clindamycin, imipenem, clarithromycin); switch to po to complete 60 days (1 agent)	Cipro 500 BID or doxycycline 100 mg BID for 60 days, plus 3-dose regimen of anthrax vaccine (available through CDC, IND protocol)	If organism susceptible to penicillin, PEP for pregnant women and children can be changed to oral amoxicillin
<b>Brucellosis</b>	<ul style="list-style-type: none"> <li>• Febrile prodrome</li> <li>• Osteoarticular disease,</li> <li>• Genitourinary infection</li> <li>• Hepatitis</li> <li>• Endocarditis and CNS involvement rarely</li> </ul>	5-60 days, occasionally months	Serum; blood, bone marrow (BSL-2)	Serology; culture	Standard precautions; contact isolation if draining lesions	Doxycycline 200 mg/d po plus rifampin 600-900 mg/d po x 6wk	Doxycycline and rifampin for 3 wks. if inadvertently inoculated	Trimethoprim-sulfamethoxazole can be substituted for rifampin, although 30% relapse rate

Contact the Division of Disease Control at 215-685-6741 M-F, 8:30a.m. – 5:00p.m. (215-686-4514 after hours and on weekends and holidays) to report suspected cases, access diagnostic testing or obtain more information.

<b>Plague</b>	<ul style="list-style-type: none"> <li>Pneumonic: fulminant pneumonia, septicemia</li> <li>Bubonic less likely</li> </ul>	2-3 days	Blood, sputum, lymph node aspirate; serum (BSL-2/3)	Gram, Wright, Giemsa or FA stain; culture; Serology	Pneumonic: droplet precautions until patient treated for 3 days	Streptomycin 1gIM twice daily x 10 days, or gentamicin, doxycycline, ciprofloxacin, chloramphenicol	Doxycycline 100 mg po q 12 h x 7 days; ciprofloxacin 500 mg po BID x 7 days	Vaccine not protective against pneumonic infection
<b>Q Fever</b>	<ul style="list-style-type: none"> <li>Fever,</li> <li>Systemic symptoms</li> <li>Pneumonia</li> <li>Hepatosplenomegaly</li> </ul>	10-40 days	Serum (BSL-2)	Serology	Standard	Tetracycline 500 mg po QID x 5-7 days; doxycycline 100 mg po BID x 5-7 days	Doxycycline or tetracycline: start 8-12 d postexposure x 5 days	Vaccine available - investigational
<b>Tularemia</b>	<ul style="list-style-type: none"> <li>Ulceroglandular</li> <li>Typhoidal (septicemic): fever, weight loss, pneumonia</li> </ul>	2-10 days	Serum; Blood, sputum, ulcer swab, lymph node aspirate (BSL-2/3)	Serology; Gram stain, culture (PCR and DFA if available)	Standard	Streptomycin 1g IM twice daily, or gentamicin 5 mg/kg IM or IV daily or ciprofloxacin x 10 days; OR doxycycline or chloramphenicol x 14 days	Doxycycline 100 mg po q 12hrs x 14 days; Ciprofloxacin 500 mg po twice daily X 14 days	Transfer culture to BSL-3 after initial isolation of organism
<b>Smallpox</b>	<ul style="list-style-type: none"> <li>Fever</li> <li>Systemic toxicity</li> <li>Vesicular rash with centrifugal distribution</li> <li>Lesions synchronous in stage of development</li> </ul>	7-17 days	Pharyngeal swab, vesicular fluid, scab material (BSL-4)	ELISA, PCR, viral isolation	Airborne	None (cidofovir effective in vitro)	Vaccine within 4 days of exposure, VIG (0.6 ml/kg IM within 3 days) if vaccine contraindicated	Preexposure and post-exposure vaccination recommended if > 3 yrs since last vaccination
<b>Viral encephalitis</b>	<ul style="list-style-type: none"> <li>VEE: fever, headache, malaise, photophobia, vomiting</li> <li>WEE/EEE: febrile prodrome, somnolence, delirium</li> </ul>	<ul style="list-style-type: none"> <li>VEE 2-6 days</li> <li>WEE/EEE 7-14 days</li> </ul>	Serum; CSF (BSL-2)	Serology; Viral isolation	Standard	Supportive	None	Vaccines available, although poorly immunogenic
<b>Viral hemorrhagic fevers</b>	<ul style="list-style-type: none"> <li>Fever,</li> <li>myalgia,</li> <li>hypotension,</li> <li>hemorrhagic features</li> </ul>	4-21 days	Serum; blood, formalin-fixed tissue biopsy (BSL-4)	Serology; Viral isolation, PCR, immunobiological detection of antigen in tissue	Contact precautions (consider additional precautions if massive hemorrhage)	Supportive; ribavirin for CCHF/arenaviruses; antibody passive for AHF, BHF, Lassa, CCHF	None	Aggressive management of hypotension, secondary infections

Contact the Division of Disease Control at 215-685-6741 M-F, 8:30a.m. – 5:00p.m. (215-686-4514 after hours and on weekends and holidays) to report suspected cases, access diagnostic testing or obtain more information.

<b>Botulinum</b>	<ul style="list-style-type: none"> <li>Ocular symptoms</li> <li>Skeletal muscle paralysis – symmetric, descending</li> <li>Respiratory failure</li> </ul>	1-5 days	Serum, stool (BSL-2), gastric aspirate, vomitus	Mouse bioassay for toxin detection; culture	Standard	DOD heptavalent antitoxin serotypes A-G; CDC trivalent equine antitoxin serotypes A, B, E	None	Skin testing for hypersensitivity before equine antitoxin administration
<b>Staphylococcal enterotoxin B</b>	<ul style="list-style-type: none"> <li>Fever</li> <li>Headache</li> <li>Cough</li> <li>Respiratory distress</li> <li>GI symptoms</li> </ul>	1-6 hours	Nasal swab, serum, urine (BSL-2)	Antigen detection (toxin) – ELISA; serology	Standard precautions	Supportive	None	Vomiting and diarrhea may occur if toxin is swallowed

**Important contact information:**

Philadelphia Department of Public Health.....215-685-6741; After-hours on-call: 215-686-4514

Philadelphia Police/Fire/Emergency.....911

Poison Control Center.....800-222-1222

Pennsylvania Department of Health.....1-877-PA-HEALTH

Contact the Division of Disease Control at 215-685-6741 M-F, 8:30a.m. – 5:00p.m. (215-686-4514 after hours and on weekends and holidays) to report suspected cases, access diagnostic testing or obtain more information.